GLUCAGON
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Sep 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
GLUCAGON by Eli Lilly and Company is receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Approved for severe hypoglycemia in pediatric. First approved in 1998.
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Glucagon is an injectable small-molecule hormone that treats severe hypoglycemia in pediatric patients by stimulating glycogen breakdown and glucose release from the liver. It works by activating glucagon receptors to rapidly elevate blood glucose levels during hypoglycemic emergencies. The drug also has extrahepatic effects including smooth muscle relaxation in the gastrointestinal tract.
LOE Approaching
As LOE approaches, the brand team is likely focused on lifecycle management and preparing for generic/biosimilar competition; expect smaller, more defensive commercial operations.
Mechanism of Action
receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and…
Indications (1)
Clinical Trials (20)
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Started May 2026
300 enrolled
Obesity or Overweight
Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist
Started Apr 2026
50 enrolled
Laxity; Skin
Glucagon Resistance in Patients With MASLD and T2DM
Started Jan 2026
24 enrolled
Metabolic Associated Fatty Liver DiseaseType 2 Diabetes (T2DM)
Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists
Started Nov 2025
24 enrolled
Wrinkle
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
Started Oct 2025
10 enrolled
glp1 AgonistGene ExpressionSkin Laxity
Worked on GLUCAGON at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.